Probiotic therapy, which has been developed to reverse gut dysbiosis associated with AD (Vogt et al., 2017; Lin et al., 2018), has the potential of correcting tau hyperphosphorylation through GSK-3β suppression (Hooper et al., 2008; Lin R. et al., 2020; Figure 1). Here, MAPT is linked to Alzheimer disease.